Jerome Zacks
Cardiovascular Disease · New York, NYNPI 1114904505
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,080 of the $22,467 with a category attached, or 80.5%. 21 manufacturers reported payments, led by Lexicon Pharmaceuticals, Inc. at 52.1% of the total. Reporting peaked in 2019 at $11,708 and has fallen 81.0% since, to $2,228 in 2022. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 118 payments — averaging $190.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lexicon Pharmaceuticals, Inc.$12K
- Tersera Therapeutics LLC$9K
- Johnson & Johnson$335
- AstraZeneca$292
- Abbott$286
- Bayer$181
- plus $855 from 15 others
What the payments were for
- Consulting fees$18,08080%
- Speaking & faculty fees$1,8908%
- Travel & lodging$310%
- Food & beverage$2,46211%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lexicon Pharmaceuticals, Inc. | 19 | $11,717 |
| Tersera Therapeutics LLC | 7 | $8,802 |
| Johnson & Johnson(2 entities) | 18 | $335 |
| AstraZeneca | 15 | $292 |
| Abbott | 3 | $286 |
| Bayer | 14 | $181 |
| Amgen | 7 | $155 |
| Astellas Pharma US Inc | 6 | $127 |
| Pfizer | 4 | $98 |
| Novo Nordisk | 5 | $95 |
| Novartis | 4 | $89 |
| Aytu Biopharma, Inc. | 5 | $86 |
| Zyla Life Sciences, Inc. | 2 | $42 |
| Coloplast | 2 | $39 |
| Urovant Sciences Inc | 1 | $30 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Clarus Therapeutics Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Metuchen Pharmaceuticals | 1 | $13 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xermelo$11,350
- AMPLATZER Occluders$193
How this compares
$22,467 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New York
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Megha PrasadNew York$813K
- Eyal HerzogNew York$645K
- Nisha JhalaniNew York$443K
- Roxana MehranNew York$432K
- Howard WeintraubNew York$328K
- Anuradha Lala-TrindadeNew York$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.